• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Effects and mechanism of eleutheroside E on the growth of human hypertrophic scar fibroblasts].刺五加苷E对人增生性瘢痕成纤维细胞生长的影响及其机制
Zhonghua Shao Shang Za Zhi. 2021 Mar 20;37(3):279-287. doi: 10.3760/cma.j.cn501120-20200219-00072.
2
[Expression and effect of microRNA-627 in human hypertrophic scar].微小RNA-627在人增生性瘢痕中的表达及作用
Zhonghua Shao Shang Za Zhi. 2021 Apr 20;37(4):369-376. doi: 10.3760/cma.j.cn501120-20200225-00090.
3
[Expression and effect of microRNA-205 in human hypertrophic scar].[微小RNA-205在人增生性瘢痕中的表达及作用]
Zhonghua Shao Shang Za Zhi. 2021 Feb 20;37(2):180-186. doi: 10.3760/cma.j.cn501120-20200219-00071.
4
[Effects of silencing Smad ubiquitination regulatory factor 2 on the function of human hypertrophic scar-derived fibroblasts].沉默Smad泛素化调节因子2对人增生性瘢痕来源成纤维细胞功能的影响
Zhonghua Shao Shang Za Zhi. 2017 Mar 20;33(3):145-151. doi: 10.3760/cma.j.issn.1009-2587.2017.03.004.
5
[Effects of transforming growth factor β1 receptor inhibitor SD-208 on human hypertrophic scar].转化生长因子β1受体抑制剂SD-208对人增生性瘢痕的影响
Zhonghua Shao Shang Za Zhi. 2016 Jul 20;32(7):389-95. doi: 10.3760/cma.j.issn.1009-2587.2016.07.002.
6
[Expression and effect of microRNA-205 in hypertrophic scar].微小RNA-205在增生性瘢痕中的表达及作用
Zhonghua Shao Shang Za Zhi. 2021 Jan 22;37(2):E006. doi: 10.3760/cma.j.issn.1009-2587.2021.0006.
7
[Mechanism of transcriptional regulation of Meox1 by transforming growth factor β (1) and its effect on cell migration of adult human dermal fibroblasts].[转化生长因子β(1)对Meox1的转录调控机制及其对成人皮肤成纤维细胞迁移的影响]
Zhonghua Shao Shang Za Zhi. 2020 Mar 20;36(3):224-233. doi: 10.3760/cma.j.cn501120-20200109-00014.
8
[Expression of microRNA-296 in rabbit hypertrophic scars and its role to human fibroblasts].[微小RNA-296在兔增生性瘢痕中的表达及其对人成纤维细胞的作用]
Zhonghua Shao Shang Za Zhi. 2021 Aug 20;37(8):725-730. doi: 10.3760/cma.j.cn501120-20210420-00142.
9
[Effects of transient receptor potential vanilloid type 4-specific activator on human vascular endothelial cell functions and blood supply of rat perforator flap and its mechanism].[瞬时受体电位香草酸亚型4特异性激活剂对人血管内皮细胞功能及大鼠穿支皮瓣血供的影响及其机制]
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022 May 20;38(5):434-446. doi: 10.3760/cma.j.cn501120-20210419-00138.
10
[Proliferation of hypertrophic scar fibroblasts inhibited by microRNA-627 targeting IGF-Ⅰin hypertrophic scar].微小RNA-627靶向胰岛素样生长因子-Ⅰ抑制增生性瘢痕成纤维细胞增殖在增生性瘢痕中的作用
Zhonghua Shao Shang Za Zhi. 2021 Mar 24;37:1-8. doi: 10.3760/cma.j.issn.501120-20200225-00090.

本文引用的文献

1
The therapeutic effect of Interleukin-18 on hypertrophic scar through inducing Fas ligand expression.白细胞介素-18 通过诱导 Fas 配体表达对增生性瘢痕的治疗作用。
Burns. 2021 Mar;47(2):430-438. doi: 10.1016/j.burns.2020.07.008. Epub 2020 Jul 15.
2
The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation.皮肤肥厚性瘢痕和瘢痕疙瘩形成中的肾素-血管紧张素系统
Exp Dermatol. 2020 Sep;29(9):902-909. doi: 10.1111/exd.14154. Epub 2020 Aug 5.
3
The Effects of Timing of Postoperative Radiotherapy on Hypertrophic Scar in a Rabbit Model.术后放疗时机对兔增生性瘢痕的影响。
Med Sci Monit. 2020 Jul 17;26:e921263. doi: 10.12659/MSM.921263.
4
Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation.针对 TGF-β/Smad 信号通路的当前潜在治疗策略,以减轻瘢痕疙瘩和增生性瘢痕的形成。
Biomed Pharmacother. 2020 Sep;129:110287. doi: 10.1016/j.biopha.2020.110287. Epub 2020 Jun 12.
5
Targeted apoptosis of myofibroblasts by elesclomol inhibits hypertrophic scar formation.靶向肌成纤维细胞的凋亡可抑制肥大性瘢痕形成。
EBioMedicine. 2020 Apr;54:102715. doi: 10.1016/j.ebiom.2020.102715. Epub 2020 Apr 3.
6
The efficacy of bleomycin for treating keloid and hypertrophic scar: A systematic review and meta-analysis.博来霉素治疗瘢痕疙瘩和增生性瘢痕的疗效:一项系统评价和荟萃分析。
J Cosmet Dermatol. 2020 Dec;19(12):3357-3366. doi: 10.1111/jocd.13390. Epub 2020 Apr 3.
7
Modulating cationicity of chitosan hydrogel to prevent hypertrophic scar formation during wound healing.调节壳聚糖水凝胶的正电荷密度以防止伤口愈合过程中的增生性瘢痕形成。
Int J Biol Macromol. 2020 Jul 1;154:835-843. doi: 10.1016/j.ijbiomac.2020.03.161. Epub 2020 Mar 17.
8
Notch signal deficiency alleviates hypertrophic scar formation after wound healing through the inhibition of inflammation. Notch 信号缺失通过抑制炎症缓解创伤愈合后的增生性瘢痕形成。
Arch Biochem Biophys. 2020 Mar 30;682:108286. doi: 10.1016/j.abb.2020.108286. Epub 2020 Jan 30.
9
Downregulation of CFTR Is Involved in the Formation of Hypertrophic Scars.CFTR 的下调参与了肥厚性瘢痕的形成。
Biomed Res Int. 2020 Jan 2;2020:9526289. doi: 10.1155/2020/9526289. eCollection 2020.
10
The influence of GSTT/GSTM null genotypes in scarring.谷胱甘肽S-转移酶T1/谷胱甘肽S-转移酶M1缺失基因型对瘢痕形成的影响。
Med Pharm Rep. 2019 Dec;92(Suppl No 3):S73-S77. doi: 10.15386/mpr-1513. Epub 2019 Dec 15.

刺五加苷E对人增生性瘢痕成纤维细胞生长的影响及其机制

[Effects and mechanism of eleutheroside E on the growth of human hypertrophic scar fibroblasts].

作者信息

Lin S X, Guo B Y, Hui Q, Tao K

机构信息

Department of Burns and Plastic Surgery, General Hospital of Northern Theater Command, Shenyang 110016, China.

出版信息

Zhonghua Shao Shang Za Zhi. 2021 Mar 20;37(3):279-287. doi: 10.3760/cma.j.cn501120-20200219-00072.

DOI:10.3760/cma.j.cn501120-20200219-00072
PMID:33706429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11917272/
Abstract

To investigate the effects and mechanism of eleutheroside E on the growth of human hypertrophic scar fibroblasts (Fbs). The experimental research method was used. The hypertrophic scar tissue was collected from 6 patients with hypertrophic scar (1 male and 5 females, aged 20 to 51 (37±8) years) admitted to General Hospital of Northern Theater Command, from October 2018 to March 2019. The third to seventh passages of human hypertrophic scar Fbs were cultured for later experiments. Cells were divided into normal saline group, 100 μmol/L eleutheroside E group, 200 μmol/L eleutheroside E group, and 400 μmol/L eleutheroside E group, and normal saline, eleutheroside E at the final molarity of 100, 200, and 400 μmol/L were added to cells in the corresponding groups. Cells were collected and divided into small interfering RNA (siRNA)-negative control alone group, siRNA-thrombospondin 1 (THBS1) alone group, siRNA-negative control400 μmol/L eleutheroside E group, and siRNA-THBS1400 μmol/L eleutheroside E group. Cells in siRNA-negative control alone group and siRNA-negative control400 μmol/L eleutheroside E group were transfected with siRNA-negative control, cells in siRNA-THBS1 alone group and siRNA-THBS1400 μmol/L eleutheroside E group were transfected with siRNA-THBS1. At 24 h after transfection, cells in siRNA-negative control alone group and siRNA-THBS1 alone group were added with normal saline, and cells in siRNA-negative control400 μmol/L eleutheroside E group and siRNA-THBS1400 μmol/L eleutheroside E group were added with eleutheroside E at the final molarity of 400 μmol/L. At 0 (immediately), 12, 24, 36, and 48 h after treatment, the cell proliferation activity (expressed as absorbance value) was detected by thiazolyl blue assay. Cells were divided into normal saline group, 200 μmol/L eleutheroside E group, 400 μmol/L eleutheroside E group, siRNA-negative control alone group, siRNA-THBS1 alone group, siRNA-negative control400 μmol/L eleutheroside E group, and siRNA-THBS1400 μmol/L eleutheroside E group. The corresponding treatments in each group were the same as before. At 24 h after treatment, the apoptosis was observed by Hoechst 33258 staining. Cells were collected and divided into normal saline group, 100 μmol/L eleutheroside E group, 200 μmol/L eleutheroside E group, 400 μmol/L eleutheroside E group, siRNA-negative control alone group, siRNA-THBS1 alone group, siRNA-negative control400 μmol/L eleutheroside E group, and siRNA-THBS1400 μmol/L eleutheroside E group. The corresponding treatments in each group were the same as before. At 24 h after treatment, the THBS1 protein level of cells was detected by Western blotting. The number of sample in each group was all 3 at each time point. Data were statistically analyzed with analysis of variance for factorial design, one-way analysis of variance, independent sample test, and Bonferroni correction. At 0 h after treatment, the absorbance values of cells in normal saline group, 100 μmol/L eleutheroside E group, 200 μmol/L eleutheroside E group, and 400 μmol/L eleutheroside E group were similar (0.05). At 12, 24, 36, and 48 h after treatment, the absorbance values of cells in 100 μmol/L eleutheroside E group, 200 μmol/L eleutheroside E group, and 400 μmol/L eleutheroside E group were significantly lower than those of normal saline group (7.64, 28.94, 13.69, 5.87, 6.96, 22.83, 14.75, 11.52, 21.09, 20.15, 29.52, 23.12, 0.05 or 0.01). At 0 h after treatment, the absorbance values of cells in siRNA-negative control alone group, siRNA-THBS1 alone group, siRNA-negative control400 μmol/L eleutheroside E group, and siRNA-THBS1400 μmol/L eleutheroside E group were similar (0.05). At 12, 24, 36, and 48 h after treatment, the absorbance values of cells in siRNA-THBS1 alone group and siRNA-negative control400 μmol/L eleutheroside E group were significantly lower than those in siRNA-negative control alone group (7.14, 44.87, 20.67, 40.98, 9.26, 11.08, 15.33, 20.56, 0.05 or 0.01); the absorbance values of cells in siRNA-THBS1 alone group, siRNA-negative control400 μmol/L eleutheroside E group, and siRNA-THBS1400 μmol/L eleutheroside E group were similar (0.05). Compared with that in normal saline group, the numbers of apoptotic cells in 200 μmol/L eleutheroside E group and 400 μmol/L eleutheroside E group were increased at 24 h after treatment. At 24 h after treatment, compared with that in siRNA-negative control alone group, the numbers of apoptotic cells in siRNA-THBS1 alone group and siRNA-negative control400 μmol/L eleutheroside E group were increased, while the numbers of apoptotic cells in siRNA-THBS1 alone group, siRNA-negative control400 μmol/L eleutheroside E group, and siRNA-THBS1400 μmol/L eleutheroside E group were similar. At 24 h after treatment, the protein levels of THBS1 of cells in 100 μmol/L eleutheroside E group, 200 μmol/L eleutheroside E group, and 400 μmol/L eleutheroside E group (0.87±0.12, 0.38±0.07, 0.20±0.09) were significantly lower than 1.83±0.17 in normal saline group (16.61, 16.17, 17.29, 0.01). At 24 h after treatment, the protein levels of THBS1 of cells in siRNA-THBS1 alone group and siRNA-negative control400 μmol/L eleutheroside E group (0.61±0.07, 0.58±0.07) were significantly lower than 1.86±0.07 in siRNA-negative control alone group (71.06, 83.80, 0.01), and the protein levels of THBS1 of cells siRNA-THBS1 alone group, siRNA-negative control400 μmol/L eleutheroside E group, and siRNA-THBS1400 μmol/L eleutheroside E group (0.63±0.11) were similar (0.05). Eleutheroside E can inhibit the growth of human hypertrophic scar Fbs by down-regulating the expression of THBS1.

摘要

探讨刺五加苷E对人增生性瘢痕成纤维细胞(Fbs)生长的影响及其机制。采用实验研究方法。收集2018年10月至2019年3月北部战区总医院收治的6例增生性瘢痕患者(男1例,女5例,年龄20~51(37±8)岁)的增生性瘢痕组织。培养人增生性瘢痕Fbs的第三代至第七代用于后续实验。将细胞分为生理盐水组、100μmol/L刺五加苷E组、200μmol/L刺五加苷E组和400μmol/L刺五加苷E组,分别向相应组细胞中加入终浓度为100、200和400μmol/L的生理盐水、刺五加苷E。收集细胞并分为单纯小干扰RNA(siRNA)阴性对照组、siRNA-血小板反应蛋白1(THBS1)组、siRNA阴性对照400μmol/L刺五加苷E组和siRNA-THBS1400μmol/L刺五加苷E组。单纯siRNA阴性对照组和siRNA阴性对照400μmol/L刺五加苷E组细胞转染siRNA阴性对照,单纯siRNA-THBS1组和siRNA-THBS1400μmol/L刺五加苷E组细胞转染siRNA-THBS1。转染后24 h,单纯siRNA阴性对照组和单纯siRNA-THBS1组细胞加入生理盐水,siRNA阴性对照400μmol/L刺五加苷E组和siRNA-THBS1400μmol/L刺五加苷E组细胞加入终浓度为400μmol/L的刺五加苷E。处理后0(即刻)、12、24、36和48 h,采用噻唑蓝法检测细胞增殖活性(以吸光度值表示)。将细胞分为生理盐水组、200μmol/L刺五加苷E组、400μmol/L刺五加苷E组、单纯siRNA阴性对照组、单纯siRNA-THBS1组、siRNA阴性对照400μmol/L刺五加苷E组和siRNA-THBS1400μmol/L刺五加苷E组。每组相应处理同前。处理后24 h,采用Hoechst 33258染色观察细胞凋亡情况。收集细胞并分为生理盐水组、100μmol/L刺五加苷E组、200μmol/L刺五加苷E组、400μmol/L刺五加苷E组、单纯siRNA阴性对照组、单纯siRNA-THBS1组、siRNA阴性对照400μmol/L刺五加苷E组和siRNA-THBS1400μmol/L刺五加苷E组。每组相应处理同前。处理后24 h,采用蛋白质免疫印迹法检测细胞THBS1蛋白水平。每个时间点每组样本数均为3。数据采用析因设计方差分析、单因素方差分析、独立样本t检验及Bonferroni校正进行统计学分析。处理后0 h,生理盐水组、100μmol/L刺五加苷E组、200μmol/L刺五加苷E组和400μmol/L刺五加苷E组细胞吸光度值相似(P>0.05)。处理后12、24、36和48 h,100μmol/L刺五加苷E组、200μmol/L刺五加苷E组和400μmol/L刺五加苷E组细胞吸光度值均显著低于生理盐水组(P<0.05或P<0.01)。处理后0 h,单纯siRNA阴性对照组、单纯siRNA-THBS1组、siRNA阴性对照400μmol/L刺五加苷E组和siRNA-THBS1400μmol/L刺五加苷E组细胞吸光度值相似(P>0.05)。处理后12、24、36和48 h,单纯siRNA-THBS1组和siRNA阴性对照400μmol/L刺五加苷E组细胞吸光度值均显著低于单纯siRNA阴性对照组(P<0.05或P<0.01);单纯siRNA-THBS1组、siRNA阴性对照400μmol/L刺五加苷E组和siRNA-THBS1400μmol/L刺五加苷E组细胞吸光度值相似(P>0.05)。与生理盐水组相比,处理后24 h,200μmol/L刺五加苷E组和400μmol/L刺五加苷E组凋亡细胞数增加。处理后24 h,与单纯siRNA阴性对照组相比,单纯siRNA-THBS1组和siRNA阴性对照4